Source: Eur Respir J, 54 (4) 1900982; 10.1183/13993003.00982-2019
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Helen R. Stagg, Graham H. Bothamley, Jennifer A. Davidson, Heinke Kunst, Maeve K. Lalor, Marc C. Lipman, Miranda G. Loutet, Stefan Lozewicz, Tehreem Mohiyuddin, Aula Abbara, Eliza Alexander, Helen Booth, Dean D. Creer, Ross J. Harris, Onn Min Kon, Michael R. Loebinger, Timothy D. McHugh, Heather J. Milburn, Paramita Palchaudhuri, Patrick P.J. Phillips, Erik Schmok, Lucy Taylor, Ibrahim Abubakar. Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance. Eur Respir J, 54 (4) 1900982; 10.1183/13993003.00982-2019

Member's Comments

No comment yet.

Related content which might interest you: Is adding fluoroquinolones to regimens for treating isoniazid-resistant tuberculosis necessary? Source: Eur Respir J, 54 (4) 1901494; 10.1183/13993003.01494-2019 Year: 2019 Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Source: Eur Respir J 2008; 31: 904-905 Year: 2008 Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis Source: Eur Respir J 2015; 46: 444-455 Year: 2015 Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience Source: Eur Respir J 2016; 47: 333-336 Year: 2016 Tuberculosis 1995–2004: evaluation of the resistance of mycobacterium tuberculosis to anti-TBC drugs in Greece Source: Eur Respir J 2006; 28: Suppl. 50, 589s Year: 2006 Considerations upon the drug resistance spectrum of Mycobacterium tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 313s Year: 2001 Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity? Source: Eur Respir J, 49 (5) 1700738; 10.1183/13993003.00738-2017 Year: 2017 Extensively drug-resistant tuberculosis: back to the future Source: Eur Respir J 2010; 36: 475-477 Year: 2010 Genotypes and drug resistance patterns of multi-drug-resistant mycobacterium tuberculosis strains in Pakistan Source: International Congress 2015 – Non-tuberculous mycobacteria and molecular microbiology Year: 2015 Extensively drug-resistant tuberculosis: early access to bedaquiline for a UK patient Source: Eur Respir J 2014; 43: 292-294 Year: 2004 Facilities for treating multidrug-resistant tuberculosis (MDRTB) in Europe Source: International Congress 2016 – New insights into aspects of tuberculosis epidemiology Year: 2016 Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis Source: Eur Respir J, 57 (4) 2004454; 10.1183/13993003.04454-2020 Year: 2021 Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis? Source: Eur Respir J 2016; 48: 582-585 Year: 2016 WHO guidance on multidrug-resistant tuberculosis treatment: using and communicating the evidence Source: Eur Respir J, 55 (3) 1902325; 10.1183/13993003.02325-2019 Year: 2020 Multidrug-resistant tuberculosis in children: evidence from global surveillance Source: Eur Respir J 2013; 42: 701-707 Year: 2013 Immunological response in HIV-associated tuberculosis and the implications of HIV in the search for a tuberculosis vaccine Source: Annual Congress 2007 - Tuberculosis control and HIV in Europe: good or bad news? Year: 2007 Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India Source: Eur Respir J 2012; 39: 956-962 Year: 2012 Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2013; 42: 504-512 Year: 2013 Mycobacterium tuberculosis drug resistance surveillance in Belarus Source: Eur Respir J 2005; 26: Suppl. 49, 199s Year: 2005 Characteristics of drug susceptibility testing for bedaquline and clofazimine of 178 drug-resistant Mycobacterium tuberculosis isolates in Japan Source: International Congress 2019 – Drug-resistant tuberculosis Year: 2019